key: cord-1022116-ng2pwk0a
authors: Henry, Brandon Michael; Aggarwal, Gaurav; Wong, Johnny; Benoit, Stefanie; Vikse, Jens; Plebani, Mario; Lippi, Giuseppe
title: Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis
date: 2020-05-27
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.05.073
sha: 799ce3c3e14179fe19c9a06d84e9af028b08493e
doc_id: 1022116
cord_uid: ng2pwk0a

Coronavirus disease 2019 (COVID-19) infection has now reached a pandemic state, affecting more than a million patients worldwide. Predictors of disease outcomes in these patients need to be urgently assessed to decrease morbidity and societal burden. Lactate dehydrogenase (LDH) has been associated with worse outcomes in patients with viral infections. In this pooled analysis of 9 published studies (n = 1532 COVID-19 patients), we evaluated the association between elevated LDH levels measured at earliest time point in hospitalization and disease outcomes in patients with COVID-19. Elevated LDH levels were associated with a ~6-fold increase in odds of developing severe disease and a ~16-fold increase in odds of mortality in patients with COVID-19. Larger studies are needed to confirm these findings.

J o u r n a l P r e -p r o o f 4 Introduction:

The current pandemic of coronavirus disease 2019 (COVID-19) originally emerged from China, but has since then infected more than 1 million patients worldwide, with over 400,000 cases in the US alone 1 . This condition is associated with high morbidity, leading to significant strain on healthcare infrastructure and resources. The associated fatality rate is also higher than other respiratory viral infections. Hence, it is necessary to urgently identify reliable predictors of disease severity and mortality for careful allocation of healthcare resources and to enable earlier clinical intervention and monitoring to improve clinical outcomes.

Various biomarkers are currently under investigation for their role in determination of prognosis in patients with COVID-19. Lactate dehydrogenase (LDH) is one such biomarker of interest, especially since elevated LDH levels have been associated with worse outcomes in patients with other viral infections in the past [2] [3] [4] . Early data in COVID-19 patients has suggested significant differences in LDH levels between patients and without severe disease 5 . Hence, we performed a pooled analysis of the published literature to explore the possible association between increased LDH values and odds of disease severity and mortality in COVID-19 patients.

A comprehensive search of literature on online databases Medline (PubMed interface), Web of Science, EMBASE and Scopus, using no language restriction, was conducted with the search terms "lactate dehydrogenase" OR "LDH" AND "COVID-19" OR "coronavirus 2019" OR "SARS-CoV-2" until April 3, 2020. References of all identified studies were investigated to J o u r n a l P r e -p r o o f 5 determine other eligible studies. The reporting of this study was performed in compliance with the PRISMA guidelines (Preferred reporting items for systematic reviews and meta-analyses).

The PRISMA Checklist is shown in supplement 1.

All resulting documents were assessed by title, abstract, and full text for observational studies reporting frequency data on LDH values at admission or earliest time point in hospitalization in COVID-19 patients with or without severe disease or in non-survivors and survivors by two independent reviewers. "Severe disease" was clinically defined as patients requiring life support, meeting criteria for acute respiratory distress syndrome (ARDS), need for mechanical ventilation, or intensive care unit (ICU) admission. An acceptable study level definition of elevated LDH with an upper limit cut-off in the range of 240-255 U/L was required. Studies fitting the criteria were included in a pooled analysis. Studies with a higher than 255 U/L cutoff for abnormality were excluded to avoid biasing the analysis via threshold effect. Additional data was sought from study authors when appropriate.

Pooled analysis was performed with MetaXL, software version 5.3 (EpiGear International Pty Ltd., Sunrise Beach, Australia), using an random effects model to estimate the odds ratio (OR) and 95% confidence interval (95%CI) of elevated LDH levels in association with severe versus non-severe COVID-19 and non-survival vs survival. A leave-one-out sensitivity analysis was performed to determine sources of heterogeneity amongst studies. We also performed a metaregression analysis to assess the impact of age on association of elevated LDH levels with J o u r n a l P r e -p r o o f 6 disease severity and mortality. When unavailable, mean and standard deviation of LDH levels were extrapolated from sample size, median and interquartile range (IQR), according to Hozo et al 6 . Publication bias analysis was performed using funnel plot analysis. The study was carried out in accordance with the declaration of Helsinki and with the terms of local legislation.

A total of 289 studies were initially found, out of which 208 were excluded due to repetition.

Another 63 were removed as they did not report LDH values. 18 studies were left, out of which 9

were removed because they were review articles or editorials. Nine studies (four case-control studies and five retrospective cohort studies) with 1532 patients, were finally used in the pooled Table 1 . Five studies did not report LDH values for all included patients; the study level samples used are presented in Table 1 .

Seven studies compared elevated LDH values in severe vs. non-severe cases in a total of 1206 patients, 188 (15.6%) of whom had severe disease outcome 7-9,11-14 . A total of 600 patients 8, 9 . Pooled analysis showed about ~6. 5 Figure 3 ). Funnel plot analysis indicate some asymmetry amongst studies suggestive of publication bias, however, limited studies exclude firm conclusions (Figure 4 ).

Three studies compared elevated LDH values with survival and non-survival in 514 patients, 157 (30.5%) of whom were non-survivors 10, 13, 15 

The results of our pooled analysis demonstrate an association between elevated LDH values and worse outcomes in patients with COVID-19. Specifically, there was a more than 6-fold increase in odds of severe disease and a more than 16-fold increase in odds of mortality in patients with elevated LDH. Furthermore, in all the three studies reporting mortality as an outcome, elevated LDH levels were found in more than 95% of non-survivors compared to less than 60% of survivors.

LDH is an intracellular enzyme found in cells in almost all organ systems, which catalyzes the interconversion of pyruvate and lactate, with concomitant interconversion of NADH and NAD + . 16 The enzyme is composed by two major subunits (i.e., A and B), and is present in has not been determined. Additionally, LDH levels are elevated in thrombotic microangiopathy, which is associated with renal failure and myocardial injury [18] [19] [20] . Elevated d-dimer levels and thrombocytopenia in patients with severe COVID-19 have also been reported, which suggests a hypercoagulable state may be contributing to severity of illness and mortality 21, 22 .

Multiple studies have found LDH to be a predictor of worse outcomes in hospitalized patients 2, 23 . Many of the prognosticators and therapies currently being studied for COVID-19 are based on experience with the previous coronavirus outbreak, Severe Acute Respiratory Syndrome (SARS), or with other viral respiratory infections. LDH levels were also found to be elevated in patients with Middle East Respiratory Syndrome (MERS) 24 . Elevated LDH levels seem to reflect that the multiple organ injury and failure may play a more prominent role in this pathology in influencing the clinical outcomes in patients with COVID-19.

Our study has some limitations, such as the small number of studies with limited sample sizes.

There was heterogeneity in the LDH data, likely due to the poor standardization of analytical methods and poor description in "Material and Methods" section of the analytical performances, including different methods of measurement. To account for heterogeneity among studies, we performed sensitivity analysis. We also performed funnel plot analysis to assess for publication bias. Finally, all the studies were from China and hence the findings may not be applicable to other populations. Larger studies from other countries are needed to confirm our findings. In the meantime, we suggest that LDH level may be used as an important tool in determining prognosis in patients with COVID-19. Since LDH measurement is based on a colorimetric method, quick Journal Pre-proof processing of multiple samples can be done using computer automation which may help in quick triage of COVID-19 patients 25 .

In our pooled analysis, elevated LDH values were associated with 6-fold increased odds of severe COVID-19 disease. More importantly, elevated LDH was associated with a more than 16fold increase in odds of mortality. As such, patients' LDH should be closely monitored for any of signs of disease progression or decompensation. Since the LDH levels used in the study were at admission or earliest time during hospitalization, admission LDH levels could be considered for inclusion in future risk stratification models for COVID-19 severity and mortality. Larger studies are needed to confirm these findings. 

World Health Organization. Coronavirus disease 2019 (COVID-19) pandemic

Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome

Eight-month prospective study of 14 patients with hospital-acquired severe acute respiratory syndrome

Viral infection in community acquired pneumonia patients with fever: a prospective observational study

Hematologic, biochemical and immune marker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID 19): a meta-analysis

Estimating the mean and variance from the median, range, and the size of a sample

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Clinical Features of 69 Cases with Coronavirus Disease

Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19). medRxiv

Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cancer cell metabolism: Warburg and beyond

Death after graft loss: an important late study endpoint in kidney transplantation

Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome

A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study